Device Trial Radar · NCT06567795
PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG
Last checked: Nov 19, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
189
Planned (sponsor's estimate)
Start
Mar 14, 2024
Primary completion
Mar 18, 2026
Study completion Mar 18, 2027
Sponsor
- Lead sponsor
- Aventusoft, LLC.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Aug 23, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.
Conditions
- Diabetes Mellitus Type 2
- Cardiovascular Diseases
- Coronary Artery Disease
- Cerebrovascular Disease
- Peripheral Artery Disease
Interventions
HemotagDevice
Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration.Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Metabolic Research Institute, Inc
West Palm Beach, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.